98%
921
2 minutes
20
Objective: To assess the prevalence, course, and predictors of depression in patients with systemic sclerosis (SSc).
Methods: We conducted a comprehensive search in November 2006 of MEDLINE, PsycINFO, and CINAHL databases to identify original research studies published in any language that used a structured interview or validated questionnaire to assess major depressive disorder or clinically significant symptoms of depression in patients with SSc. The search was augmented by hand searching 26 selected journals through December 2006 and references from identified articles and reviews. Studies were excluded if only an abstract was provided or if depression was not measured by a validated method.
Results: No studies used a structured clinical interview to assess the prevalence of major depressive disorder. The prevalence of clinically significant depressive symptoms was 51-65% based on 2 studies that used a Beck Depression Inventory (BDI) score >or=10 and 46-56% based on 2 studies that used a BDI score >or=11. These rates and those reported in 4 other studies that used different assessment tools (36-43%) were consistently high compared with other medical patient groups assessed with the same instruments and cutoffs. Methodologic issues limited the ability to draw strong conclusions from studies of predictors.
Conclusion: Symptoms of depression are common among patients with SSc. The high rates reported across studies suggest that routine screening is recommended. There is a need for studies that examine depression at different time points from the diagnosis of SSc and that systematically investigate factors associated with high levels of depressive symptoms.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/art.22910 | DOI Listing |
JAMA Psychiatry
September 2025
Denovo Biopharma LLC, San Diego, California.
Importance: This study represents a first successful use of a genetic biomarker to select potential responders in a prospective study in psychiatry. Liafensine, a triple reuptake inhibitor, may become a new precision medicine for treatment-resistant depression (TRD), a major unmet medical need.
Objective: To determine whether ANK3-positive patients with TRD benefit from a 1-mg and/or 2-mg daily oral dose of liafensine, compared with placebo, in a clinical trial.
Int Urogynecol J
September 2025
Department of Public Health Sciences, University of Connecticut School of Medicine, Farmington, CT, USA.
Introduction And Hypothesis: Depressive and anxiety symptoms are known risk factors for lower urinary tract symptoms (LUTS). To inform prevention and treatment strategies, this research examined whether greater emotional support seeking weakened associations of affective symptoms with LUTS and poorer bladder health.
Methods: Data were collected from women in the USA who participated in the RISE FOR HEALTH study of bladder health.
Metab Brain Dis
September 2025
Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277, Jiefang Avenue, Wuhan, Hubei, 430022, China.
Major depression disorder (MDD) is a mental condition that significantly threatens both physical and psychological health. This study aimed to discern variances in plasma metabolic profiles between MDD sufferers and healthy counterparts. Additionally, we tracked the hospitalization journey of MDD patients to investigate the normalization of metabolic irregularities through conventional treatment in the form of self-control.
View Article and Find Full Text PDFSpiritual interventions, including meditation, prayer, mindfulness, and compassionate care, have gained increasing attention for their potential to enhance both psychological resilience and overall health. This systematic review and meta-analysis examined eight eligible studies conducted across the USA, Europe, and China to assess the impact of such interventions on key outcomes, namely anxiety reduction, quality of life, chronic disease symptom management, and patient satisfaction. Seven studies contributed quantitative data.
View Article and Find Full Text PDFArch Gynecol Obstet
September 2025
Faculty of Medicine, University of Lille, 59000, Lille, France.
Purpose: Endometriosis is a chronic, hormone-dependent disease affecting up to 10% of women of reproductive age, often associated with chronic pelvic pain (CPP). Neuropathic pain has been increasingly recognized as a significant component in a subset of patients with CPP related to endometriosis. The study objective was to assess the prevalence of neuropathic-like pain in women with deep endometriosis (DE) and CPP, and to analyze its influence on pain perception and quality of life.
View Article and Find Full Text PDF